Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
86 results about "Innate immune system" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The innate immune system is one of the two main immunity strategies found in vertebrates (the other being the adaptive immune system). The innate immune system is an older evolutionary defense strategy, relatively speaking, and it is the dominant immune system response found in plants, fungi, insects, and primitive multicellular organisms.
Methods and compositions for inducing innate immune responses
InactiveUS20090017021A1Heavy metal active ingredientsOrganic active ingredientsImmunostimulating ComplexesInnate immune system
Owner:COLEY PHARMA GRP INC +1
Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
ActiveUS20100021416A1Reduce dosing frequencyReduce riskBiocideSenses disorderDiseaseControlled release
Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
Owner:OTONOMY INC +1
Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
InactiveUS20060140936A1Antibacterial agentsOrganic active ingredientsDendritic cellAutoimmune condition
Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.
Owner:IMMUNOMEDICS INC
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
ActiveUS20160237134A1Low immunogenicityEnhance protein expressionDepsipeptidesOxidoreductasesBiotechnologyUracil
The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
Owner:MODERNATX INC
Transfection results of non-viral gene delivery systems by influencing of the innate immune system
The innate immune system of eukaryotes is able to recognise foreign genetic material by means of Toll-like receptors and to initiate signal transduction cascades that trigger an antiviral state of cell populations by way of an interferon response. That antiviral state is also a barrier for non-viral gene delivery systems. If the signal transduction cascade is interrupted intracellularly or intercellularly, transfection efficiencies of non-viral gene delivery systems can be increased and undesirable changes in the expression profile can be avoided. Since RNA-interference is to be attributed to the antiviral state, the RNAi machinery is likewise activated after activation of the innate immune system. In that way, knock-down efficiencies on transfection with siRNA can be increased.
Owner:BIONTEX LAB
Targeted biocides
InactiveUS20050014932A1Sure easyPrevent relapseBiocideAntibody mimetics/scaffoldsInnate immune systemReceptor molecule
The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense.
Owner:IOGENETICS
Cancer therapy using whole glucan particles and antibodies
InactiveUS20060165700A1Enhances tumoricidal activityHigh activityBiocideOrganic active ingredientsInnate immune systemCytotoxicity
The present invention relates to methods of using whole glucan particles and complement activating antibodies for antitumor therapy. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines.
Owner:BIOPOLYMER ENG +2
Innate immune system-directed vaccines
InactiveUS20070122421A1Stimulating innate immune responseEnhancing adaptive immune responseBacteriaVirus peptidesAntigenInnate immune system
The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response.
Owner:YALE UNIV
Flagellin polypeptide vaccines
InactiveUS20090297552A1Facilitates cellular uptakeSsRNA viruses negative-senseAntibacterial agentsAntigenImmunomodulatory peptide
Vaccines that comprise or generate immunomodulatory flagellin polypeptides able to stimulate an innate immune response intracellularly and extracellularly employ viruses, bacteria or parasitic cells that contain expression systems for such polypeptides, as well as fusion proteins that contain antigens and / or cell penetrating peptides along with the immunomodulatory peptide.
Owner:INSTITUTE FOR SYSTEMS BIOLOGY
Innate immune system-directed vaccines
InactiveUS20080226667A1Improve responseEnhancing adaptive immune responseBacterial antigen ingredientsViral antigen ingredientsAntigenInnate immune system
The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response.
Owner:YALE UNIV
Innate immune system-directed vaccines
InactiveUS20070160623A1Stimulating innate immune responseEnhancing adaptive immune responseAntibody mimetics/scaffoldsTissue cultureAntigenInnate immune system
The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response.
Owner:MEDZHITOV RUSLAN M +1
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
ActiveUS9751925B2Maximizes contentEnhanced ability to produceDepsipeptidesOxidoreductasesBiotechnologyUracil
The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
Owner:MODERNATX INC
Use of compositions to enhance innate immune response
InactiveUS20090088373A1Enhance innate immune system responseInduce antibiotic resistanceBiocideCyclic peptide ingredientsCalciferolsInnate immune system
The present invention discloses methods of using of compounds for the enhancement of the innate immune system of a patient. In particular, the active compounds of the present invention include at least one calcineurin inhibitor, mTOR inhibitor or non-immunosuppresive derivative, or a derivative, isomer, or pharmaceutically acceptable salt thereof; and optionally, at least one calciferol or LMW inhibitor, or a derivative, isomer, or pharmaceutically acceptable salt thereof. Pharmaceutical formulations comprising same are also disclosed.
Owner:GALLO RICHARD L +2
Cancer therapy using whole glucan particles and antibodies
InactiveUS20100166751A1Enhances tumoricidal activityHigh activityOrganic active ingredientsAntibody ingredientsInnate immune systemFactor ii
Owner:BIOTHERA INC (US)
Targeted biocides
The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzyme) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense.
Owner:IOGENETICS +1
Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
InactiveUS20050074449A1Deleterious immune responseAvoid immune responseBiocidePowder deliveryAntigenAutoimmune condition
Owner:NOVARTIS FARMA
Orthotopic, controllable, and genetically tractable non-human animal model for cancer
InactiveUS20090022685A1High resolutionBiocideOrganic active ingredientsAbnormal tissue growthCooperative interaction
This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations (e.g., in oncogenes and tumor suppressor genes) that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both, preferably by inducible, reversible, and / or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene, and by transplanting the resulting hepatocytes into a recipient non-human animal. The invention further provides a method to treat cancer involving cooperative interactions between a tumor cell senescence program and the innate immune system.
Owner:COLD SPRING HARBOR LAB INC
Plant defense signal peptides
InactiveUS20090300802A1Increase productionImprove the immunityBiocideSugar derivativesInnate immune systemElicitor
Owner:WASHINGTON STATE UNIVERSITY
Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
InactiveUS20080108794A1Antibacterial agentsOrganic active ingredientsDendritic cellAutoimmune condition
Owner:IMMUNOMEDICS INC
Compositions and methods for activating innate and allergic immunity
ActiveUS20090318337A1Altering hyperreactive responseElicit and enhance innate immune responseAntibacterial agentsAntimycoticsAnaphylaxisClinical settings
Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).
Owner:ID BIOMEDICAL CORP LAVAL
Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants
InactiveUS20070059319A1Stimulating innate immune systemEnhancing innate immunityBiocideMicrobiological testing/measurementInnate immune systemToll-like receptor binding
A method of screening for agents that stimulate the innate immune system in mammals employs markers that respond to Toll-like receptor binding. Agents identified in the assay boost both innate and adaptive immune responses, when administered alone or in combination with vaccines.
Owner:NOVASCREEN BIOSCI
Modulation of an innate immune response by altering TRIAL-R signaling
InactiveUS7892539B2Organic active ingredientsPeptide/protein ingredientsDendritic cellInnate immune system
Methods and composition are provided for modulating innate immunity by modulating activation of the TRAIL receptor. Signaling through the TRAIL-R inhibits the responsiveness of cells including dendritic cells, macrophages, and the like. The activity of these cells is increased or decreased by the administration of agents that inhibit or activate TRAIL-R signaling. Innate immunity includes the production of cytokines that act on the immune system.
Owner:RGT UNIV OF CALIFORNIA
Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
InactiveUS20080241141A1Antibacterial agentsOrganic active ingredientsDendritic cellAutoimmune condition
Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.
Owner:IMMUNOMEDICS INC
Drugs including anticancer agents and immunopotentiators and health foods and drinks
InactiveUS20050129789A1Avoid seizuresEnhancing immune systemBiocideUnknown materialsCancer preventionAnticarcinogen
It has been proven that a fruit of the genus Malus such as apple (Malus domestica) and crabapple (Malus pumila), a fruit of the genus Pyrus, or a substance derived therefrom, when administered, has the actions of enhancing innate immune system such as natural killer cells, macrophages and the like, activity of lymphocytes, to thus control cancer-attacked cells, as well as to prevent carcinogenesis of cells not yet affected by cancer, and when taken regularly, further has an effect of preventing the onset of cancer, i.e., having a cancer-preventing effect. It has been further proven that both a mature apple and an immature apple, or an immature apple alone has a similar action of preventing the onset of cancer.
Owner:SHIROTA YASUYUKI
Compositions and methods for activating innate and allergic immunity
Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).
Owner:ID BIOMEDICAL CORP LAVAL
Drug delivery compositions and uses thereof
ActiveUS20190083626A1Prevent relapseMinimizing adverse side effectOrganic active ingredientsPeptide/protein ingredientsCancer preventionLymphatic Spread
Provided are drug delivery compositions and devices useful for the treatment and / or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and / or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.
Owner:DANA FARBER CANCER INST INC
Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
The present invention relates to compositions and methods of using whole glucan particles and agents. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines and enhances the bodies response to the agent.
Owner:UNIV OF LOUISVILLE RES FOUND INC +1
Preventing and treating amyloid-beta deposition by stimulation of innate immunity
ActiveUS20110060035A1Preventing and reducing amyloid depositionReducing amyloid depositionOrganic active ingredientsNervous disorderCereblonInnate immune system
The present invention is directed to a method of preventing or reducing amyloid deposition in a subject. This method involves selecting a subject with amyloid deposits and stimulating the innate immune system of the selected subject under conditions effective to reduce the amyloid deposits. Also disclosed is a method of preventing or treating cerebral amyloidosis and Alzheimer's Disease in a subject by administering to the selected subject an agent that stimulates the innate immune system. In addition, a composition useful for the stimulation of the innate immune system of a subject exhibiting symptoms associated with amyloid deposition is disclosed.
Owner:NEW YORK UNIV
Compositions and methods for modulating innate and adaptive immune systems
InactiveUS20150299252A1Strong cytotoxicityPeptidesAntibody ingredientsInnate immune systemT lymphocyte
Compositions and methods useful in modulating the innate and adaptive immune systems in a subject, including activation of natural killer (NK) cells and / or CD8+ cytotoxic T lymphocytes. The method typically comprises: administering to the subject a composition comprising a therapeutic peptide or a multivalent structured polypeptide comprising multiple copies of the therapeutic peptide described herein in an amount sufficient to increase activity of NK cells and / or CD8+ cytotoxic T lymphocytes in the subject. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide or a multivalent structured polypeptides of the invention. In certain embodiments, the composition further comprises an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject. In other embodiments, the compositions are administered in a therapeutically effective amount to a subject in need thereof to treat rheumatoid arthritis.
Owner:SUSAVION BIOSCI
Constructs and methods for delivering molecules via viral vectors with blunted innate immune responses
ActiveUS20160222414A1Increase gene expressionLower immune responseSugar derivativesGenetic therapy composition manufactureInnate immune systemNucleotide
A CpG-modified recombinant adeno-associated viral (AAV) vector is described. The vector carries a nucleic acid molecule comprising AAV inverted terminal repeat (ITR) sequences and an exogenous gene sequence under the control of regulatory sequences which control expression of the gene product, in which the nucleic acid sequences carried by the vector are modified to significantly reduce CpG di-nucleotides such that an immune response to the vector is reduced as compared to the unmodified AAV vector. Also provided are methods and regimens for delivering transgenes using these AAV viral vectors, in which the innate immune response to the vector and / or transgene is significantly modulated.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com